# Junta clínica — PT-pseudo_47c373e230b6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47c373e230b6",
  "pid": "PT-pseudo_47c373e230b6",
  "task": 1,
  "psa": 10.0,
  "age": 75,
  "months": 1,
  "pirads": "5",
  "psad": 0.27,
  "psav": 1.78,
  "psap": 8.3,
  "vol": 41.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7478973,
  "medhx": "Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "180 cm",
    "bmi": "20.4",
    "bp": "122/66 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (18 pack-yr, quit 2006)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "09 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment."
    },
    {
      "s": "History",
      "t": "A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Widowed",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "12 units / week",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47c373e230b6
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.27 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7478973 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.

Vitals: weight 66 kg, height 180 cm, BMI 20.4, BP 122/66 mmHg, HR 73 bpm. Smoking: Ex-smoker (18 pack-yr, quit 2006).

Chief complaint: Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment.

History: A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12.

Physical examination: Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour.

Patient info: warehouse manager; Widowed; Lives with partner; adult children visit weekly.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review; Radiology — chest X-ray (routine).
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.68
  uncertainty  +/- 0.16 (95% CI 0.36-0.99); among patients it cannot tell apart the outcome was 0.91 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses the use of MRI and biopsy in relation to PI-RADS scores and PSA density. It states, "A PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific risk stratification variables that the guideline uses, such as the PSA density threshold of $0.15 \text{ ng/mL/cc}$ mentioned in the context of risk-adapted pathways. The classifier's bid is blind to the guideline's recommendation to use risk-based pathways that can avoid biopsy in low-risk profiles.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is $\ge 3$, which triggers biopsy according to the guideline.
The PSA trend - The PSA velocity is $1.78 \text{ ng/mL/yr}$, which is a factor that the guideline mentions in relation to risk-based pathways.
The previous notes - The previous notes state the prior biopsy was "Positive," which is a decisive factor that the guideline makes decisive regarding repeat biopsy.
The laboratory results - The PSA density is $0.27 \text{ ng/mL/cc}$, which is above the $0.15 \text{ ng/mL/cc}$ threshold mentioned in the guideline.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 5 and elevated PSA velocity, combined with the prior positive biopsy, mandate a repeat biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion characteristics and extension.
  psa_trend (get_psa_trend) -> Determine the full PSA trajectory beyond the headline value.
  previous_notes (get_previous_notes) -> Clarify the specific management plan agreed upon following the prior positive biopsy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension?
  Q2. How does the PSA trend inform the risk-adapted pathway decision?
  Q3. What is the management context detailed in the previous notes regarding the prior positive biopsy?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a 41.0 mL organ with a discrete 14 mm focus in the left mid-gland peripheral zone with PI-RADS 5.
psa_trend
The PSA trend shows values: {"date": "Nov 2022", "val": 9.1}, {"date": "Aug 2023", "val": 2.8}, {"date": "May 2024", "val": 6.3}, {"date": "Feb 2025", "val": 10.0}.
previous_notes
The previous notes clarify that following a positive biopsy result indicating low-grade disease, the patient was directed to urology for detailed assessment, involving routine PSA tracking and yearly check-ups.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the key variables (PSA density) were already provided in the structured panel, and the moderator did not specifically ask for the full panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report shows a PI-RADS 5 designation, which triggers biopsy according to the EAU guideline.
PSA trend shows a rising trajectory, which is a factor the guideline mentions in relation to risk-adapted pathways.
previous_notes state the prior biopsy was positive, which is a decisive factor that the guideline makes decisive regarding repeat biopsy.
AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The combination of a PI-RADS 5, rising PSA velocity, and a prior positive biopsy strongly points toward a need for further investigation.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1, Q2, and Q3 by opening the `radiology_report`, `psa_trend`, and `previous_notes`, respectively. However, the `laboratory_results` document remains closed, which was noted as containing the PSA density, a variable the Expert-EAU mentioned as relevant.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-Classifier's suggestion of BIOPSY, as the registrar noted that the PI-RADS 5 triggers biopsy per the EAU guideline, and the prior positive biopsy is a decisive factor.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension? Answered by the registrar via the `radiology_report`, which showed a 14 mm focus in the left mid-gland peripheral zone with PI-RADS 5.
Q2. How does the PSA trend inform the risk-adapted pathway decision? Answered by the registrar via the `psa_trend`, which showed a rising trajectory, a factor the guideline mentions.
Q3. What is the management context detailed in the previous notes regarding the prior positive biopsy? Answered by the registrar via the `previous_notes`, which stated the patient was directed to detailed assessment following the positive result.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 score, which directly triggers biopsy per the EAU guideline, and the prior positive biopsy result, which is a decisive factor in the guideline regarding repeat biopsy. The PSA trend is also relevant because the guideline mentions it in relation to risk-adapted pathways. The guideline does not explicitly support deferral based on these findings alone.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the combination of a PI-RADS 5 and a prior positive biopsy strongly points toward a need for further investigation according to the guideline's framework.

VERDICT: ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the PI-RADS 5 score from the mpMRI and the rising PSA trend necessitate further investigation per the EAU guideline. The combination of a PI-RADS 5 and the prior positive biopsy strongly points toward a need for further investigation. The decision to biopsy is supported by the retrieved evidence indicating a need to characterize the known disease further.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
